ReviewFrontiers in pharmacology2025
From molecules to medicine: a systematic review of Gastrodia elata's bioactive metabolites and therapeutic potential.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bioactivity-guided optimization of Gastrodia elata cultivation: integrated modulation of spawn wood length, tree species and pit size.Journal of natural medicines · 2026Article
- Comparative Evaluation of Phenolic Composition and Antioxidant Activities ofFoods (Basel, Switzerland) · 2026Article
- Six New Phenolic Compounds in Ethyl Acetate Extract of Tall Gastrodia Tuber (Tianma) with Four Compounds Screened Preliminarily for Cytoprotective Effects Against Excitotoxicity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Comparative Analysis of Components and Biological Activities in Different Parts ofMetabolites · 2026Article
- Article
- Differential sensitivity to strigolactone signaling and identification of putative D14/KAI2-like receptors in symbioticFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dried tuber of Gastrodia elata (GE), a perennial orchid with a 2,200-year medicinal history documented in the Shennong Bencaojing (200 BCE), remains a cornerstone of traditional Chinese medicine (TCM) and contemporary integrative therapies across Asia. Initially prescribed for neurological disorders (e.g., epilepsy, stroke prophylaxis) and hypertension, modern research has expanded its therapeutic portfolio to include anti-aging, antitumor, and osteoprotective applications. This systematic review synthesizes 1) traditional ethnopharmacological uses, 2) phytochemical profiling of 100+ identified bioactive metabolites (e.g., gastrodin, parishins), and 3) mechanistic insights into their pharmacokinetic behaviors and pharmacodynamic actions. Notably, botanical drug interactions in TCM formulations enhance gastrodin's blood-brain barrier penetration, elucidating clinical efficacy. While
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.